您当前的位置:
CCCP
氧化磷酸化解偶联剂,CCCP是氧化磷酸化解偶联剂。
目录号: PC12571 纯度: ≥98%
CAS No. :555-60-2
商品编号 规格 价格 会员价 是否有货 数量
PC12571-500mg 500mg ¥1470.00 请登录
Medlife所售产品仅用于科学研究(非临床研究),非药品不可食用,不可用于人体或动物的临床诊断和治疗,我们不为个人提供产品及服务。产品COA等资料,可至下方“质量控制”中下载。
中文名称
CCCP
中文别名
羰基氰酯-3-氯苯基腙;羰基氰化间氯苯腙;羰基氰化氯苯腙;羰基氰化物间氯苯腙;羰基氰基3-氯苯腙
英文名称
CCCP
英文别名
[(3-chlorophenyl)hydrazono]malononitrile;Carbonyl cyanide 3-chlorophenylhydrazone;2-[(3-chlorophenyl)hydrazinylidene]propanedinitrile;CARBONYL CYANIDE M-CHLOROPHENYL HYDRAZONE;CCCP;m-Cl-CCP;Mesoxalonitrile 3-chlorophenylhydrazone;Carbonyl cyanide m-chlorophenylhydrazone;(3-Chlorophenyl)hydrazonomalononitrile;Carbonylcyanide-3-chlorophenylhydrazone;m-Chlorophenyl carbonylcyanide hydrazone;(3-Chlorophenyl)carbonohydrazonoyl dicyanide;Propanedinitrile, [(3-chlorophenyl)hydrazono]-;Carbonyl cyanide, (3-chlorophenyl)hydra
Cas No.
555-60-2
分子式
C9H5ClN4
分子量
204.62
包装储存
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
生物活性

CCCP is an oxidative phosphorylation (OXPHOS) uncoupler. CCCP induces activation of PINK1 leading to Parkin Ser65 phosphorylation.

性状

Solid

IC50 & Target[1][2]

STING
IFN-β

体外研究(In Vitro)

CCCP inhibits IFN-β production induced by various types of the STING pathway activators. CCCP suppresses the phosphorylation of STING, TBK1, and IRF3 via disrupting the association of STING and TBK1. CCCP inhibits activation of STING and its downstream signaling molecules, TBK1 and IRF3, but not STING translocation to the perinuclear region. CCCP impairs the interaction between STING and TBK1 and concomitantly triggers mitochondria fission. Importantly, the knockout of the crucial mitochondria fission regulator Drp1 restored the STING activity, indicating that CCCP down-modulates the STING pathway through DRP1-mediated mitochondria fragmentation. The protonophore CCCP that disrupts membrane potential suppresses the DMXAA-triggered STING signaling pathway. CCCP drastically suppresses the production of IFN-β in DMXAA-treated RAW264.7 cells and MEFs.
As low as 1 μM CCCP is enough to induce mitocytosis. In cells treated with 10 μM CCCP, which is the dose used for inducing mitophagy, mitocytosis is barely induced. Mechanistically, mitocytosis requires positioning of damaged mitochondria at the cell periphery, which occurs because damaged mitochondria avoid binding to inward motor proteins.

Medlife has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究(In Vivo)

The same dosage of 3?mg/kg.bw each of CCCP and PPEF is used. In both the cases 1?log reduction is observed in the bacterial load. However, when 3?mg/kg.bw of PPEF is used in combination with 3?mg/kg.bw of CCCP, 6 log10 reduction is observed in the bacterial count. The developed model validates the enhanced antibacterial activity of combination therapy.Tc-MIBI signals in the hearts of SD rats administered CCCP (4 mg/kg intraperitoneally) or vehicle is also measured. Tc-MIBI signals decrease in rat hearts administered CCCP, and the ATP content, as measured by P magnetic resonance spectroscopy, decreased simultaneously. To investigate whether CCCP decreased the Tc-MIBI signals in rats, we analyzed the radioisotope activity of excised heart tissue from rats administered CCCP. At 180 min after Tc-MIBI injection, the Tc-MIBI signals from the hearts in the CCCP group are significantly lower than those in the vehicle group.

Medlife has not independently confirmed the accuracy of these methods. They are for reference only.

运输条件

Room temperature or refrigerated transportation.

储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
参考文献
溶解度数据
体外研究: 

DMSO : 50 mg/mL (244.36 mM; Need ultrasonic)

H2O : < 0.1 mg/mL (ultrasonic;warming;heat to 60°C) (insoluble)

配制储备溶液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 4.8871 mL 24.4355 mL 48.8711 mL
5 mM 0.9774 mL 4.8871 mL 9.7742 mL
10 mM 0.4887 mL 2.4436 mL 4.8871 mL
*

产品不同,其溶解度不同。建议根据产品选择合适的溶剂配制储备溶液;配成溶液后,建议分装保存,避免反复冻融造成的产品失效
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month。-80°C 储存时,建议在 6 个月内使用,-20°C 储存时,建议在 1 个月内使用。

体内研究:

建议根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都建议先按照 体外研究 方式配制澄清的储备液,再依次添加助溶剂:

——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用; 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶

  • 1.

    建议依照次序添加每种溶剂: 10% DMSO    40% PEG300    5% Tween-80    45% saline

    Solubility: ≥ 2.5 mg/mL (12.22 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (12.22 mM,饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀;向上述体系中加入50 μL Tween-80,混合均匀;然后继续加入 450 μL生理盐水定容至 1 mL。

    将 0.9 g 氯化钠,完全溶解于 100 mL ddH?O 中,得到澄清透明的生理盐水溶液
*
搜索质检报告(COA)

1:一般建议:溶解度为Medlife测试数据,可能与文献描述存在差异。这是由于生产工艺和批次不同产生的正常现象。为了使其更好的溶解,请用37℃加热试管并在超声波水浴中震动片刻。不同批次产品溶解度各有差异,仅做参考,具体以实验方案为准。

2:储存条件:粉末-20°C一般情况可以保存3年,溶于溶剂-80°C一般情况可以保存1年。不同产品及不同批次产品可能存在差异,请细致阅读产品信息,并辅助参考相关文献描述。

相关产品

更多
The molarity calculator equation
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
The dilution calculator equation
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2